Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial - Cortes, Javier; Schneeweiss, Andreas (The lancet. Oncology, 2015)
Gesehen am 01.08.2016